gotistobart (ONC-392)
Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.
DISCOVERY
From novel biology to clinical stage products.
Rich Pipeline
Best-in-class and first-in-class immunotherapy products targeting cancer evasion of adaptive and innate immunity.
Experienced team
Our team brings success from biotech pharma, and academia to OncoC4.
ONC-782, 783, and 784
Targeting cancer cells through chimeric antigen receptors T cells (ONC-782), bi-specific antibodies (ONC-783) and antibody-drug conjugates (ONC-784).
Exploring Our Pipeline:
OncoC4 has a pipeline of best-in-class and first-in-class immunotherapy products that are moving through preclinical testing.
Rising To The Most Pressing Challenge In Immunotherapy
Developing unique drugs that uncouple therapeutic effects and immunotherapy-related adverse effects.
Scientific discoveries drive explosive immunotherapy.
YANG LIU, PHD
CHIEF EXECUTIVE OFFICER & CHIEF SCIENTIFIC OFFICER
Latest News
OncoC4 Announces FDA Clearance of IND Application for Novel SIGLEC 10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors
ONC-841 is a potential first-in-class SIGLEC 10 antibody designed to block an innate and potentially adaptive immune checkpoint and prevent cancer evasion of immune cells Anti-tumor T cells, NK cells and macrophages can be rejuvenated within the tumor microenvironment following ONC-841 treatment Preliminary Phase 1 data on safety, pharmacokinetics, and…
OncoC4 Expands Scientific Advisory Board with Appointment of Heather A. Wakelee, MD, FASCO
Wakelee is a world-renowned expert in the research and treatment of lung cancer OncoC4’s SAB now includes 6 distinguished scientists, industry experts, and key opinion leaders in oncology and immunotherapy ROCKVILLE, Maryland, USA, April 2, 2024 — OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer, today…
OncoC4 Announces First Patient with Advanced Prostate Cancer Dosed in Phase 1/2 Trial of BioNTech-partnered BNT316/ONC-392 Program
The Phase 1/2 trial will assess the efficacy and safety of BNT316/ONC-392 in combination with the radioligand therapy lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with metastatic castration resistant prostate cancer (“mCRPC”) who have progressed on an androgen receptor (“AR”) pathway inhibitor. The trial is expected to enroll 144 patients…